Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Decreased by FORA Capital LLC

FORA Capital LLC trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 58.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,828 shares of the medical equipment provider's stock after selling 22,486 shares during the quarter. FORA Capital LLC's holdings in Zimmer Biomet were worth $1,672,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet during the 4th quarter worth about $25,000. Accredited Wealth Management LLC bought a new stake in Zimmer Biomet during the 4th quarter worth about $36,000. Kentucky Trust Co bought a new stake in Zimmer Biomet during the 4th quarter worth about $39,000. OFI Invest Asset Management bought a new stake in Zimmer Biomet during the 4th quarter worth about $40,000. Finally, Dunhill Financial LLC raised its holdings in Zimmer Biomet by 86.6% during the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 206 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

NYSE:ZBH traded up $0.11 during trading hours on Friday, hitting $95.22. 3,438,566 shares of the stock were exchanged, compared to its average volume of 1,722,258. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.92 and a 52-week high of $122.25. The firm's fifty day moving average price is $104.43 and its 200 day moving average price is $106.13. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a market cap of $18.84 billion, a P/E ratio of 21.40, a P/E/G ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The company had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the prior year, the firm earned $1.94 earnings per share. The firm's revenue was up 1.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were paid a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ZBH. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the company a "buy" rating in a report on Tuesday, May 6th. Morgan Stanley dropped their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, The Goldman Sachs Group lowered their target price on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet currently has an average rating of "Hold" and an average target price of $114.15.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.39% of the company's stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.